StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

Stock analysts at StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Galmed Pharmaceuticals in a research note on Friday.

Galmed Pharmaceuticals Price Performance

Shares of GLMD opened at $1.34 on Friday. The business has a 50-day moving average of $2.22 and a 200-day moving average of $3.17. The company has a market capitalization of $862,960.00, a price-to-earnings ratio of -0.08 and a beta of 0.70. Galmed Pharmaceuticals has a 1 year low of $1.28 and a 1 year high of $23.80.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 76.14% of the stock is currently owned by institutional investors.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.